Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Read More
Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
A new assay for the quantification of MRD in CLL can detect MRD to 10-5 and below, allowing further stratification of patient ...
Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
A new study suggests small extracellular vesicles secreted by leukemia cells reduce anti-tumor T-cell responses during CLL ...
Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
Next-line CAR-T or venetoclax-based therapy led to longer OS than other approved next-line treatments in patients with CLL ...
Leah SherwoodChronic Lymphocytic Leukemia | October 18, 2022
The CHMP of the EMA has issued a positive opinion recommending approval of zanubrutinib for the treatment of adult patients ...
Cecilia BrownChronic Lymphocytic Leukemia | October 13, 2022
Mazie Tsang, MD, MAS, MS, an Assistant Professor at the Mayo Clinic in Phoenix, Arizona, spoke with Blood Cancers Today about ...
Leah SherwoodChronic Lymphocytic Leukemia | October 10, 2022
Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology.
Leah SherwoodChronic Lymphocytic Leukemia | October 4, 2022
Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting.
Leah SherwoodChronic Lymphocytic Leukemia | October 3, 2022
Alexey V. Danilov, MD, PhD, spoke with Blood Cancers Today about his 2022 SOHO Annual Meeting presentation.
Leah SherwoodChronic Lymphocytic Leukemia | September 30, 2022
Jennifer R. Brown, MD, PhD, talks about her plans for the presidency in the upcoming year at the 2022 SOHO Annual Meeting.
Kerri FitzgeraldChronic Lymphocytic Leukemia | September 30, 2022
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Cecilia BrownChronic Lymphocytic Leukemia | September 29, 2022
HOUSTON – Thomas Kipps, MD, PhD, Professor of Medicine at the University of California, San Diego Moores Cancer Center ...
Kerri FitzgeraldChronic Lymphocytic Leukemia | September 13, 2022
President-Elect Jennifer R. Brown, MD, PhD, will take office during the 10th Annual SOHO Conference. Dr. Brown spoke with ...
Cecilia BrownChronic Lymphocytic Leukemia | August 25, 2022
Zanubrutinib led to significant improvements in progression-free survival compared with bendamustine plus rituximab for ...
Leah SherwoodChronic Lymphocytic Leukemia | August 16, 2022
The U.S. Food and Drug Administration (FDA) has approved the new tablet formulation of acalabrutinib for all current ...
Leah SherwoodChronic Lymphocytic Leukemia | August 16, 2022
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib in an all-oral, fixed-duration ...
Cecilia BrownPrint | August 8, 2022
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Leah SherwoodChronic Lymphocytic Leukemia | August 5, 2022
This article discusses the state of the art of how to manage the most difficult cases of chronic CLL with a focus on two ...
Leah SherwoodChronic Lymphocytic Leukemia | July 6, 2022
Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.
Kerri FitzgeraldAcute Myeloid Leukemia | June 23, 2022
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Advertisement
Editorial Board

Advertisement